Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M217,704Revenue $M58,831Net Margin (%)15.6Z-Score3.2
Enterprise Value $M230,929EPS $3.7Operating Margin %18.5F-Score6
P/E(ttm))23.2Cash Flow Per Share $0Pre-tax Margin (%)18.3Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %3.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %4.2Current Ratio1.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-1.1ROA % (ttm)7.3Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)12.3Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M2,447ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Dodge & Cox 2014-06-3051,102,2192.094.4+10.04%
NVS Jean-Marie Eveillard 2014-06-3013,06000
NVS PRIMECAP Management 2014-06-3023,846,2360.972.4-0.7%
NVS Tweedy Browne 2014-06-30288,8250.010.56-0.92%
NVS John Hussman 2014-06-30214,0000.011.5-3.25%
NVS Mario Gabelli 2014-06-3010,24000-4.66%
NVS Lee Ainslie 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Novartis: Ten Years of Solid ROE Jul 31 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
      Sarah Ketterer’s Causeway International Value’s Top Five Holdings Jun 05 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks May 29 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      These Three Pharmaceutical Companies Shake The Market With Their Deal Apr 27 2014 
      The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
      PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
      Diversification, Growth and Undervalued Stocks – Utilizing GuruFocus’ Global Gurus Apr 09 2014 


      More From Other Websites
      Predicting PARADIGM-HF, Or What To Expect When You're Expecting Aug 27 2014
      [video] A sensor to swallow with your medicine Aug 25 2014
      Novartis experts and future scientific leaders meet at International BioCamp 2014 to consider 'The... Aug 25 2014
      Novartis to Invest $35M in Gamida Cell for 15% Equity Aug 20 2014
      Novartis provides drug candidate compounds to TB Alliance » Aug 20 2014
      Why Novartis (NVS) Stock Is Gaining Today Aug 19 2014
      Novartis to invest in Israel's Gamida Cell, could buy out company Aug 19 2014
      [video] Eyeball injections equal eye-popping profits Aug 14 2014
      Cancer: Unpronounceable Drugs, Incomprehensible Prices Aug 13 2014
      Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its... Aug 11 2014
      Novartis loses new bid to dismiss U.S. lawsuit over kickbacks Aug 07 2014
      Novartis loses new bid to dismiss U.S. lawsuit over kickbacks Aug 07 2014
      KAE609 shows promise as next generation treatment for malaria » Jul 31 2014
      Novartis Malaria Pill Shows Promise as Best Drugs Fail Jul 30 2014
      Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help... Jul 29 2014
      Novartis Division Gets European Approval for Simbrinza Jul 28 2014
      Top Biotechnology Stocks Jul 23 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK